^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Apoptosis inhibitor

    Related drugs:
    1d
    Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis. (PubMed, J Immunother Cancer)
    Nearly half of patients developing ir-hepatitis had an inadequate response to steroids and needed MMF as a secondary immunosuppressant. Patients with mixed DILI were more likely to respond to steroids, while alcohol consumption was associated with inadequate steroid response. Immune analyses showed high T cell infiltration in the liver among patients with ir-hepatitis.
    Journal • Checkpoint inhibition
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • NCAM1 (Neural cell adhesion molecule 1) • FOXP3 (Forkhead Box P3)
    8d
    Somatostatin Effect on Growth Factors in Hepatocellular Carcinoma. (PubMed, Curr Issues Mol Biol)
    Eighteen patients with advanced Primary Biliary Cholangitis (stage III and IV) before and after Ursodeoxycholic acid (UDCA) treatment were also studied...It was not significantly increased in HCC, but it was reduced by octreotide and was increased after UDCA. In this retrospective observational study, somatostatin and its analog octreotide have a significant effect on several growth factors involved in HCC pathogenesis.
    Journal
    |
    IGF1 (Insulin-like growth factor 1) • GAST (Gastrin 2)
    10d
    Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency (clinicaltrials.gov)
    P1, N=12, Recruiting, Children's Hospital Medical Center, Cincinnati
    New P1 trial
    |
    IL18 (Interleukin 18) • XIAP (X-Linked Inhibitor Of Apoptosis)
    16d
    Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections. (clinicaltrials.gov)
    P2, N=300, Recruiting, Valenta Pharm JSC
    New P2 trial
    18d
    CHILURSO: Efficacy of Ursodeoxycholic Acid versus Corticosteroids for the Treatment of Cholestatic Hepatitis Secondary to Immunotherapy (2025-521317-50-00)
    P2/3, N=94, Not yet recruiting, Centre Hospitalier Universitaire De Montpellier
    New P2/3 trial
    29d
    Synergistic Neuroprotective Effects of Taurine and Tauroursodeoxycholic Acid on the Neurovascular Unit in Hypoxia-Reoxygenation Injury. (PubMed, Rejuvenation Res)
    Furthermore, they acted together on the p38 mitogen-activated protein kinase (MAPK) signaling pathway, and the addition of the p38 inhibitor SB203580 partially inhibited the expression of p38MAPK. Thus, the combined action of these drugs protected the NVU.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9) • IL1B (Interleukin 1, beta) • TJP1 (Tight Junction Protein 1) • CLDN5 (Claudin 5)
    1m
    Tauro ursodeoxycholic acid (TUDCA) inhibits human fibrosarcoma HT-1080 cell invasion through MMPs inactivation and the modulation of the MAPKs signaling pathway. (PubMed, Cytotechnology)
    Furthermore, gene reporter assay confirmed that TUDCA inhibited the transcriptional activity of NF-κB and AP1. These results suggest that TUDCA could exert a potent anti-metastatic activity in PMA-stimulated HT-1080 cells through modulation of MMPs, MAPKs signaling pathway, and NF-κB and AP1 transcription factors.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2)
    1m
    Targeting Mycobacterium tuberculosis GAPDH elicits potent bactericidal responses by dysregulating enzyme activity, redox dynamics and iron acquisition. (PubMed, Free Radic Biol Med)
    Overall, this study identifies the crucial function of Mtb GAPDH as a redox sensor and highlights the potential of targeting its pleiotropic cellular functions towards drug discovery. In addition, the efficacy of TCH346 provides an opportunity of drug-repurposing as a strategy for therapy.
    Journal
    |
    GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase)
    1m
    CHILURSO: Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis (clinicaltrials.gov)
    P2, N=94, Not yet recruiting, University Hospital, Montpellier
    New P2 trial
    1m
    Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Bifidobacterium Tetravaccine Live Tablets in the Treatment of Patients with Cholestatic Liver Disease (ChiCTR2500112906)
    P=N/A, N=198, Not yet recruiting, The Second Affiliated Hospital of the Army Medical University; The Second Affiliated Hospital of the Army Medical University
    New trial
    1m
    Efficacy and Safety of Ursodeoxycholic Acid in Participants with Mild to Moderate Ulcerative Colitis: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial (ChiCTR2500113946)
    P3, N=378, Not yet recruiting, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
    New P3 trial
    2ms
    Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis (clinicaltrials.gov)
    P3, N=150, Recruiting, Xijing Hospital of Digestive Diseases | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date